



生命科技集團有限公司
LifeTec Group Limited

[For Immediate Release]

LifeTec Continues To Expand Overseas Markets Solid Growth of Wei Jia Export Sales

- ◆ **Academic symposium will be held in Vietnam for Wei Jia**
- ◆ **Open Cambodia, Myanmar and Laos markets**

[2 Mar 2004] LifeTec Group Limited (“LifeTec” or the “Company” or the “Group”, HKEX Stock Code: 1180) has announced that an academic symposium for Wei Jia will be held in Vietnam by end of this month to introduce the merits of Wei Jia to liver disease experts and doctors in the country. The symposium will help to expand the Vietnam market for Wei Jia.

LifeTec has also entered into five-year exclusive distribution agreement with a Cambodian pharmaceutical importer for sales and distribution of Wei Jia in Cambodia, Myanmar and Laos. The importer is a leading drug importer and distributor in the three countries and bought 1.2 million vials of Wei Jia as the first lot for these countries. Additional orders are expected from the three markets.

About LifeTec

LifeTec is a Hong Kong listed company (stock code 1180), which develops, sells and distributes biopharmaceutical products based on original technology. LifeTec owns the intellectual property, production knowhow and worldwide exclusive distributorship of the new generation hepatitis drug Wei Jia, a Category I drug approved by China’s State Food and Drug Administration. The Company has a portfolio of promising biotech drug candidates under development.

With 120 million hepatitis B carriers, China is the world’s largest market for hepatitis drugs. Since the commercial launch of Wei Jia in mid 2001, the number of hospitals adopting Wei Jia for hepatitis treatment soared from 85 to over 600 as at the end of 2003. The substantial growth in the number of Wei Jia’s user hospitals demonstrates LifeTec’s outstanding sales and marketing capability. LifeTec is also licensed to sell and distribute third parties’

biopharmaceutical products through its nationwide distribution network.

For new product pipeline, LifeTec is working on recombinant human augments for liver regeneration (“rhALR”) and new generation antiseptic Pazufloxacin. rhALR is a revolutionary gene therapy for various kinds of liver diseases. The Institute of Infectious Diseases of the Peoples’ Liberation Army is the technical partner in the rhALR project. The Company is also developing the recombinant DNA version of Wei Jia and novel anti-fibrosis and anti-cancer compound Fibroscutum together with the City University of Hong Kong.

“LifeTec – investing in life itself” is LifeTec’s corporate motto which signifies management’s dedication to applying biotechnology for the well-being of mankind.

For Enquiries

LifeTec Group Limited

Mr. Philip Poon email: philippoon@hk1180.com
Ms. Michelle Chan email: michellechan@hk1180.com
Tel: (852) 2620 5303
Fax: (852) 2620 6000
Website: www.hk1180.com